Barinthus Biotherapeutics (BRNS) Net Income towards Common Stockholders (2020 - 2026)
Barinthus Biotherapeutics (BRNS) reported Net Income towards Common Stockholders of -$5.5 million for Q1 2026, up 71.85% on a YoY basis from -$3.2 million in Q1 2025, and up 50.16% quarter-over-quarter from -$11.1 million in Q4 2025.
Barinthus Biotherapeutics (BRNS) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Barinthus Biotherapeutics has reported Net Income towards Common Stockholders for 7 years, with the latest figure at -$5.5 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 71.85% year-over-year to -$5.5 million; the trailing twelve-month figure through Mar 2026 stood at -$52.3 million (up 19.88% YoY), and the FY2025 full-year result was -$66.5 million, down 8.62% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$5.5 million, up from -$11.1 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $15.7 million in Q2 2022, with the low at -$23.8 million in Q2 2023.
- Historically, Net Income towards Common Stockholders has averaged -$11.8 million across 5 years, with a median of -$15.5 million in 2024.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders soared 248.69% — and 2023, when it sank 807.96%.
- Barinthus Biotherapeutics' Net Income towards Common Stockholders stood at -$21.2 million in 2022, then grew by 18.3% to -$17.3 million in 2023, then decreased by 19.09% to -$20.6 million in 2024, then jumped by 46.08% to -$11.1 million in 2025, then surged by 50.16% to -$5.5 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$5.5 million (Q1 2026), -$11.1 million (Q4 2025), and -$14.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -56.48 Mn |
| 10 | Barinthus Biotherapeutics | 27.08 Mn | -40.03 Mn | - | -5.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.53 Mn |
| Dec 31, 2025 | -11.10 Mn |
| Sep 30, 2025 | -14.57 Mn |
| Jun 30, 2025 | -21.13 Mn |
| Mar 31, 2025 | -19.66 Mn |
| Dec 31, 2024 | -20.59 Mn |
| Sep 30, 2024 | -8.13 Mn |
| Jun 30, 2024 | -16.94 Mn |
| Mar 31, 2024 | -15.52 Mn |
| Dec 31, 2023 | -17.29 Mn |
| Sep 30, 2023 | -14.11 Mn |
| Jun 30, 2023 | -23.82 Mn |
| Mar 31, 2023 | -18.22 Mn |
| Dec 31, 2022 | -21.16 Mn |
| Sep 30, 2022 | 8.22 Mn |
| Jun 30, 2022 | 15.69 Mn |
| Mar 31, 2022 | 2.57 Mn |
| Dec 31, 2021 | -16.72 Mn |
| Sep 30, 2021 | -5.53 Mn |
| Jun 30, 2021 | -16.86 Mn |